Impact of Adding Midzolam to Bupavicaine 0.5% in Regional Spinal Anaesthesia on Maternal Middle Cerebral Artery Velocimetry in Parturients With Severer Preeclampsia

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04283110

Enrollment

100

Registered

2020-02-25

Start date

2019-01-12

Completion date

2020-04-05

Last updated

2020-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Midazolam in Preeclamptic Patients

Brief summary

Trial to use GABA mimetic action of midazolam to ameliorate the severe preeclampsia induced neuronal excitotoxicity using middle cerebral artery transcranial doppler resisitive vasculer indices to evaluate . Secondery goal is to study end organ injury

Interventions

DRUGintrthecl midazolam

midazolm as as adjuvant in spinal anesthesia

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender

FEMALE

Age

20 Years to 40 Years

Healthy volunteers

Inclusion criteria

* All parturients with severe preeclampsia for urgent C.S

Exclusion criteria

* Ladies refusal to participate. Refusal to have spinal anesthsia

Design outcomes

Primary

Measure	Time frame	Description
Measuring Pulsatality index and resistive index of maternal middle cerebral artery	2 months	Resistive vasculer indices outcome after intrthecal midazolam injection

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026